Faes Farma SA
MAD:FAE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Faes Farma SA
Total Current Liabilities
Faes Farma SA
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
F
|
Faes Farma SA
MAD:FAE
|
Total Current Liabilities
€184.9m
|
CAGR 3-Years
25%
|
CAGR 5-Years
17%
|
CAGR 10-Years
11%
|
|
|
Almirall SA
MAD:ALM
|
Total Current Liabilities
€350.6m
|
CAGR 3-Years
8%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
1%
|
|
|
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
|
Total Current Liabilities
€181.2m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
8%
|
CAGR 10-Years
12%
|
|
|
Laboratorio Reig Jofre SA
MAD:RJF
|
Total Current Liabilities
€101.1m
|
CAGR 3-Years
10%
|
CAGR 5-Years
5%
|
CAGR 10-Years
11%
|
|
|
L
|
Labiana Health SA
MAD:LAB
|
Total Current Liabilities
€22.2m
|
CAGR 3-Years
4%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
Faes Farma SA
Glance View
Faes Farma SA, a notable player in the pharmaceutical arena, has orchestrated its operations with the precision of a seasoned conductor. Rooted in Spain with an impressive international reach, the company blends research prowess with adept production capabilities. Central to its modus operandi is the development, manufacture, and commercialization of a wide range of pharmaceutical products and nutritional supplements. With science as its guiding star, Faes Farma dedicates substantial resources to research and development, ensuring a pipeline filled with innovative treatments that cater to diverse medical needs. The company has carved its niche by focusing on therapeutic areas such as allergy, dermatology, and the central nervous system, allowing it to create specialized solutions that resonate well with healthcare providers and patients alike. The company’s revenue engine is driven primarily by its robust product sales, enhanced by strategic partnerships and licensing agreements that bolster its market presence both in Spain and across global markets. Through rigorous production processes, Faes Farma ensures the delivery of high-quality medications, matching industry standards and fostering consumer trust. Additionally, its geographical diversification, with subsidiaries and distribution channels spreading across Europe, Latin America, and Africa, underpins its economic durability. By marrying innovation with strategic commercial tactics, Faes Farma has deftly navigated the complexities of the pharmaceutical landscape, ensuring not only profitability but also the sustained delivery of health-enhancing products to the global community.
See Also
What is Faes Farma SA's Total Current Liabilities?
Total Current Liabilities
184.9m
EUR
Based on the financial report for Dec 31, 2025, Faes Farma SA's Total Current Liabilities amounts to 184.9m EUR.
What is Faes Farma SA's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
11%
Over the last year, the Total Current Liabilities growth was 79%. The average annual Total Current Liabilities growth rates for Faes Farma SA have been 25% over the past three years , 17% over the past five years , and 11% over the past ten years .